Navigation Links
Treating Childhood Leukemia With Fewer Side Effects
Date:9/10/2009

Dutch researchers skip radiation treatments, some chemo but add corticosteroid

THURSDAY, Sept. 10 (HealthDay News) -- Adding the corticosteroid dexamethasone to the treatment regimen of children with acute lymphoblastic leukemia improves survival rates and reduces the incidence of the cancer recurring, a new Dutch study shows.

Acute lymphoblastic leukemia (ALL), a cancer of the blood, is the most common childhood cancer and is highly treatable, according to background information in the study.

But the researchers say that many children with ALL are over-treated with cranial radiation and chemotherapy drugs that cause significant side effects and may not be necessary to cure them.

The study found that a dexamethasone-based treatment can improve the cancer cure rate and reduce the risk of relapse without radiation and routinely used chemotherapy drugs. The findings were published online Sept. 9 The Lancet Oncology.

Dexamethasone is sold under the brand name Decadron.

The study involved 859 youths, aged 1 to 18, with ALL. About 30 percent of them were considered to be at high risk for recurrence.

Participants not at high risk were given a basic three-drug induction (dexamethasone, vincristine and L-asparaginase) and medium-dose methotrexate. High-risk youths were given a four-drug induction (the same three drugs as the others got plus four doses of daunorubicin), consolidation with methotrexate and two intensification courses before maintenance, which was 109 weeks for all participants.

Triple intrathecal chemo was given 13 times in those not at high risk, 15 times in high-risk youths and 17 times in those with initial central nervous system involvement. No one was given cranial radiation.

Five-year, cancer-free survival for the high-risk group was 72 percent, the study found. Those not at high risk had an 84 percent survival rate. About 70 percent of all people newly diagnosed are not at high risk, according to the researchers.

The results for those not at high risk "were achieved with high cumulative doses of dexamethasone and vincristine, but without the use of anthracyclines, etoposide, cyclophosphamide or cranial irradiation, therefore minimizing the risk of side effects," they said in a news release from the journal. The survival rate for the high-risk group also was described as favorable.

More information

The U.S. National Cancer Institute has more on acute lymphoblastic leukemia.



-- Jennifer Thomas



SOURCE: The Lancet Oncology, news release, Sept. 9, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
2. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
3. Treating diabetes during pregnancy can break link to childhood obesity
4. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
5. Treating Diabetes During Pregnancy Could Lead to Thinner Kids
6. Family-based treatment more effective than supportive psychotherapy in treating bulimia
7. Treating depression may improve recovery of heart rate variability following coronary syndromes
8. Antidepressant shows early promise in treating agitation and psychotic symptoms of dementia
9. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
10. Stem cells show promise for treating Huntingtons disease
11. Treating obstructive sleep apnea, preventing heart attacks and strokes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Treating Childhood Leukemia With Fewer Side Effects
(Date:5/26/2016)... Hampshire (PRWEB) , ... May 26, 2016 , ... ... care products, has been honored with a 2016 When Work Works Award for its ... award, part of the national When Work Works project administered by the Families and ...
(Date:5/26/2016)... D.C. (PRWEB) , ... May 26, 2016 , ... On ... men and women who lost their lives in military battle for the country. ... cards in 2015 to provide more programs that empower independence for disabled military veterans, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, the leading ... health and global clinical supply services, today announced two key appointments and the ... investment and strategic growth plans in the Asia Pacific region. , Howard Kim ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... of healthcare supply chain solutions, today announced the organization has earned its ISO ... international standards and is compliant with all rules and policies associated with ISO ...
(Date:5/26/2016)... ... May 26, 2016 , ... American orthopedic surgeon ... officer of Blue Horizon International (BHI), Brian Mehling, M.D., spoke at an International ... May 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation was focused on ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 Celsion ... drug development company, today provided an update on ... escalating clinical trial combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  GEN-1 is an IL-12 DNA plasmid ...
(Date:5/24/2016)... May 24, 2016 Los ... terapia del mundo, introduce catéteres para la intervención ... OrbusNeich, una compañía global especializada en el suministro ... expandido su cartera incluyendo productos para tratar la ... Scoreflex™ PTA son los dispositivos de primera entrada ...
(Date:5/24/2016)... -- Dutch surgeons have launched a ground-breaking medical app ... treat patients on a global scale. Medical professionals from ... and the US have already signed up for the ... a totally secure environment. Education  "Imagine a ... with a surgeon at Harvard to treat a bomb victim via ...
Breaking Medicine Technology: